Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 3Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 13Breast 9Tumor-Agnostic 6Genitourinary 5Other solid neoplasm 3CNS 3Thoracic 2Sarcoma 2Gastrointestinal 2Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Pancreatic Neoplasms 2Breast Neoplasms 2Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 218Fluorouracil 142Oxaliplatin 132Capecitabine 122pembrolizumab 113Irinotecan 110Leucovorin 104Bevacizumab 98Nivolumab 80Cisplatin 80130-nm albumin-bound paclitaxel 80Cetuximab 79Radiotherapy 78Albumin-Bound Paclitaxel 59Sorafenib 56Paclitaxel 53Cyclophosphamide 50Carboplatin 47Magnetic Resonance Spectroscopy 44Specimen Handling 39Docetaxel 37Taxes 36fludarabine 34Radiation 34durvalumab 33Ipilimumab 33Erlotinib Hydrochloride 33Biopsy 33Radiosurgery 27Folfox protocol 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × niraparib × Gastrointestinal × Clear all
NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

University of Washington

Phase 1 Active not recruiting
18 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04764084 2021-02-21

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Peking University Cancer Hospital & Institute

Phase 1 Unknown
52 enrolled
BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡